Henry Wellcome Laboratories of Structural Biology, Department of Biochemistry, University of Leicester, Leicester LE1 9HN, UK.
Nature. 2012 Jan 9;481(7381):335-40. doi: 10.1038/nature10728.
Histone deacetylase enzymes (HDACs) are emerging cancer drug targets. They regulate gene expression by removing acetyl groups from lysine residues in histone tails, resulting in chromatin condensation. The enzymatic activity of most class I HDACs requires recruitment into multi-subunit co-repressor complexes, which are in turn recruited to chromatin by repressive transcription factors. Here we report the structure of a complex between an HDAC and a co-repressor, namely, human HDAC3 with the deacetylase activation domain (DAD) from the human SMRT co-repressor (also known as NCOR2). The structure reveals two remarkable features. First, the SMRT-DAD undergoes a large structural rearrangement on forming the complex. Second, there is an essential inositol tetraphosphate molecule--D-myo-inositol-(1,4,5,6)-tetrakisphosphate (Ins(1,4,5,6)P(4))--acting as an 'intermolecular glue' between the two proteins. Assembly of the complex is clearly dependent on the Ins(1,4,5,6)P(4), which may act as a regulator--potentially explaining why inositol phosphates and their kinases have been found to act as transcriptional regulators. This mechanism for the activation of HDAC3 appears to be conserved in class I HDACs from yeast to humans, and opens the way to novel therapeutic opportunities.
组蛋白去乙酰化酶(HDACs)是新兴的癌症药物靶点。它们通过从组蛋白尾部赖氨酸残基上去除乙酰基来调节基因表达,导致染色质凝聚。大多数 I 类 HDAC 的酶活性需要募集到多亚基共抑制复合物中,而这些复合物又通过抑制性转录因子被募集到染色质上。在这里,我们报告了一个 HDAC 和一个共抑制物之间的复合物的结构,即人类 HDAC3 与人类 SMRT 共抑制物(也称为 NCOR2)的去乙酰化酶激活结构域(DAD)。该结构揭示了两个显著的特征。首先,SMRT-DAD 在形成复合物时会发生很大的结构重排。其次,有一种必需的肌醇四磷酸分子——D-肌醇-(1,4,5,6)-四磷酸(Ins(1,4,5,6)P(4))——作为两个蛋白质之间的“分子内胶”。复合物的组装显然依赖于 Ins(1,4,5,6)P(4),它可能作为一种调节剂发挥作用——这可能解释了为什么肌醇磷酸及其激酶被发现作为转录调节剂。这种激活 HDAC3 的机制似乎在从酵母到人等 I 类 HDAC 中是保守的,并为新的治疗机会开辟了道路。